Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>UBS Upgrades MEDBOT-B to Buy on Strong Overseas Sales, Expects Breakeven in 1H26
Recommend 1 Positive 1 Negative 1 |
||||
|
||||
|
According to a report from UBS, the broker was bullish on MEDBOT-B (02252.HK)'s strong overseas sales potential. MEDBOT-B's overseas revenue surged by 287% YoY last year, with sales volume of its Toumai surgical robot increasing more than fivefold. Unlike developed markets, the company focuses on middle-income developing countries in South America, South Asia, and Central and Eastern Europe, where penetration of surgical robots remains low and demand is substantial. In UBS' estimation, these regions will see cumulative installation demand for more than 10,000 laparoscopic surgical robots. As one of the market pioneers, MEDBOT-B is likely to capture a 25% market share. MEDBOT-B aims to double its total revenue in 2026 from 2025 and hike the overseas revenue contribution from 73% last year to over 80%, making it possible to achieve breakeven in 1H26. UBS has increased its target price for MEDBOT-B from HKD21.4 to HKD35.9 and upgraded its rating from Neutral to Buy. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
